바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.70 No.6
Citation Share

Diagnostic Role of C-reactive Protein, Procalcitonin and Lipopolysaccharide- Binding Protein in Discriminating Bacterial-Community Acquired Pneumonia from 2009 H1N1 Influenza A Infection

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2011, v.70 no.6, pp.490-497






& (2011). Diagnostic Role of C-reactive Protein, Procalcitonin and Lipopolysaccharide- Binding Protein in Discriminating Bacterial-Community Acquired Pneumonia from 2009 H1N1 Influenza A Infection. Tuberculosis & Respiratory Diseases, 70(6), 490-497.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: It is difficult but important to differentiate between bacterial and viral infections, especially for respiratory infections. Hence, there is an ongoing need for sensitive and specific markers of bacterial infections. We investigated novel biomarkers for discriminating community acquired bacterial pneumonia from 2009 H1N1 influenza A infections. Methods: This was a prospective, observational study of patients with community acquired bacterial pneumonia, 2009 H1N1 Influenza A infection, and healthy controls. Serum samples were obtained on the initial visit to the hospital and stored at −80℃. We evaluated CRP (C-reactive protein), PCT (procalcitonin), LBP (lipopolysaccharide- binding protein) and copeptin. These analytes were all evaluated retrospectively except CRP. Receiver operating characteristic curve (ROC) analyses were performed on the resulting data. Results: Enrolled patients included 27 with community acquired bacterial pneumonia, 20 with 2009 H1N1 Influenza A infection, and 26 who were healthy controls. In an ROC analysis for discriminating community acquired bacterial pneumonia from 2009 H1N1 influenza A infection, areas under the curve (AUCs) were 0.799 for CRP (95% Confidence interval [CI], 0.664∼0.934), 0.753 for PCT (95% CI, 0.613∼0.892) and 0.684 for LBP (95% CI, 0.531∼0.837). Copeptin was not different among the three groups. Conclusion: These findings suggest that serum CRP, PCT and LBP can assist physicians in discriminating community acquired bacterial pneumonia from 2009 H1N1 influenza A infection.

keywords
C-Reactive Protein, procalcitonin, lipopolysaccharide-binding protein, Bacteria, Influenza A Virus, C-Reactive Protein, procalcitonin, lipopolysaccharide-binding protein, Bacteria, Influenza A Virus

Reference

1.

1. Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of community- acquired pneumonia. Crit Care 2010;14:203.

2.

2. Pfäfflin A, Schleicher E. Inflammation markers in pointof- care testing (POCT). Anal Bioanal Chem 2009;393: 1473-80.

3.

3. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect of procalcitonin- guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-7.

4.

4. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-17.

5.

5. Gaïni S, Koldkjaer OG, Pedersen C, Pedersen SS. Procalcitonin, lipopolysaccharide-binding protein, interleukin- 6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care 2006;10:R53.

6.

6. Schultz MJ, Determann RM. PCT and sTREM-1: the markers of infection in critically ill patients? Med Sci Monit 2008;14:RA241-7.

7.

7. Hopstaken RM, Cals JW, Dinant GJ. Accuracy of lipopolysaccharide- binding protein (LBP) and fibrinogen compared to C-reactive protein (CRP) in differentiating pneumonia from acute bronchitis in primary care. Prim Care Respir J 2009;18:227-30.

8.

8. Schuetz P, Christ-Crain M, Müller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007;13:578-85.

9.

9. Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145-52.

10.

10. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72.

11.

11. Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011;139:1410-8.

12.

12. Ahn S, Kim WY, Yoon JY, Sohn CH, Seo DW, Kim SH, et al. Procalcitonin in 2009 H1N1 influenza pneumonia: role in differentiating from bacterial pneumonia. Tuberc Respir Dis 2010;68:205-11.

13.

13. Ingram PR, Inglis T, Moxon D, Speers D. Procalcitonin and C-reactive protein in severe 2009 H1N1 influenza infection. Intensive Care Med 2010;36:528-32.

14.

14. Park HP, Lee JS, Jang YS, Kim MS. Usefulness of procalcitonin in the assessing the severity of community- acquired pneumonia patient. Tuberc Respir Dis 2009;67:430-5.

15.

15. Christ-Crain M, Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007;30:556-73.

16.

16. Herzum I, Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008;15:581-7.

17.

17. Masiá M, Gutiérrez F, Llorca B, Navarro JC, Mirete C, Padilla S, et al. Serum concentrations of lipopolysaccharide- binding protein as a biochemical marker to differentiate microbial etiology in patients with community- acquired pneumonia. Clin Chem 2004;50: 1661-4.

18.

18. Masiá M, Gutiérrez F, Padilla S, Soldán B, Mirete C, Shum C, et al. Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect 2007;13:153-61.

19.

19. Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010;140:w13101.

20.

20. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26:2500-4.

21.

21. Darzy KH, Dixit KC, Shalet SM, Morgenthaler NG, Brabant G. Circadian secretion pattern of copeptin, the C-terminal vasopressin precursor fragment. Clin Chem 2010;56:1190-1.

22.

22. Maeder MT, Staub D, Brutsche MH, Arenja N, Socrates T, Reiter M, et al. Copeptin response to clinical maximal exercise tests. Clin Chem 2010;56:674-6.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy